Recruiting

Testing a new eye injection to reduce retinal swelling

Plain-English translation of NCT06825702 on ClinicalTrials.gov ↗ · Source last updated June 2026 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing a new treatment called , which is injected directly into the eye to reduce macular edema—swelling in the central part of the retina that can blur your vision. Researchers want to find out if this medication is safe and effective, and whether giving it every 2 weeks or every 4 weeks works better for patients. The study will enroll about 28 people and will be conducted in two main phases: first testing different dose strengths, then testing different injection schedules.

Macular edema can develop after eye surgery, from diabetes, or from inflammation and blood vessel problems in the eye, and it often leads to vision loss. Current treatment options don't always work well for everyone, so researchers are investigating whether this new medication might offer a safer or more effective alternative.

Do you qualify?

You likely qualify if…

you are between 18 and 85 years old
you have been diagnosed with macular edema caused by uveitis, retinal vein occlusion, diabetic retinopathy, or cataract surgery
your macula shows significant swelling on imaging scans
your vision is moderately to severely reduced (between 20/32 and 20/800 on standard eye charts)
you are willing to use reliable birth control for the duration of the study if you can become pregnant
you can commit to attending all study visits and follow all study instructions

You likely don't qualify if…

you have an active infection in or around your eye
you have had eye surgery or certain eye treatments in the study eye within a set timeframe before enrollment
you are pregnant, breastfeeding, or unwilling to use contraception
you have significant cloudiness of the eye's lens or other media that prevents clear imaging
you have a history of severe allergic reactions to medications injected into the eye

What participation looks like

You will receive up to three injections of the medication into your eye, spaced either 2 weeks or 4 weeks apart depending on which group you are assigned to. The study has two phases: in the first phase, researchers will test different dose strengths; in the second phase, they will test different injection schedules. Throughout the study, you will attend multiple visits for eye exams, imaging scans, and vision tests to monitor how well the treatment is working and check for any side effects.

AI-generated summary from trial data · Jun 19, 2026 · Not medical advice

Trial locations(6 sites)

Australia

Sydney Eye Hospital, Sydney, New South Wales

Sydney West Retina, Westmead, New South Wales

Royal Adelaide Hospital, Adelaide, South Australia

Hobart Eye Surgeons, Hobart, Tasmania

Centre for Eye Research Australia, East Melbourne, Victoria